- Home
- AMBC vs MLYS Comparison
AMBC vs MLYS Comparison
Compare AMBC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBC
- MLYS
- Stock Information
- Founded
- AMBC 1971
- MLYS 2019
- Country
- AMBC United States
- MLYS United States
- Employees
- AMBC N/A
- MLYS N/A
- Industry
- AMBC Property-Casualty Insurers
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- AMBC Finance
- MLYS Health Care
- Exchange
- AMBC Nasdaq
- MLYS Nasdaq
- Market Cap
- AMBC 411.3M
- MLYS 1.0B
- IPO Year
- AMBC 1991
- MLYS 2023
- Fundamental
- Price
- AMBC $8.84
- MLYS $14.37
- Analyst Decision
- AMBC Strong Buy
- MLYS Strong Buy
- Analyst Count
- AMBC 2
- MLYS 4
- Target Price
- AMBC $12.50
- MLYS $27.00
- AVG Volume (30 Days)
- AMBC 1.1M
- MLYS 846.2K
- Earning Date
- AMBC 08-04-2025
- MLYS 08-12-2025
- Dividend Yield
- AMBC N/A
- MLYS N/A
- EPS Growth
- AMBC N/A
- MLYS N/A
- EPS
- AMBC N/A
- MLYS N/A
- Revenue
- AMBC $253,912,000.00
- MLYS N/A
- Revenue This Year
- AMBC N/A
- MLYS N/A
- Revenue Next Year
- AMBC $17.41
- MLYS N/A
- P/E Ratio
- AMBC N/A
- MLYS N/A
- Revenue Growth
- AMBC 125.08
- MLYS N/A
- 52 Week Low
- AMBC $5.99
- MLYS $8.24
- 52 Week High
- AMBC $13.64
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- AMBC 75.21
- MLYS 48.90
- Support Level
- AMBC $7.01
- MLYS $14.16
- Resistance Level
- AMBC $7.46
- MLYS $15.24
- Average True Range (ATR)
- AMBC 0.41
- MLYS 0.68
- MACD
- AMBC 0.18
- MLYS 0.07
- Stochastic Oscillator
- AMBC 96.12
- MLYS 55.45
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.